Skip to content

Effect of low dose ketamine on depression and plasma BDNF in patients with lung cancer after operation

Effect of low dose esketamine on depression and plasma BDNF in patients with lung cancer after operation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049003
Enrollment
Unknown
Registered
2021-07-19
Start date
2021-07-20
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perioperative depressive mood disorder

Interventions

Es-Ketamine (group A) :Group A was given 0.5mg/kg ketamine during anesthesia induction
Normal saline group (group B):Group B was given the same dose of normal saline during anesthesia induction

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with lung cancer by preoperative or intraoperative pathology and followed by thoracoscopic partial pneumonectomy; 2. Aged 18 to 65 years, BMI 18~25, ASA I~III; 3. Have a full understanding of this study, and voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Cognitive dysfunction; 2. Schizophrenia, use of other antidepressants within the last two weeks, and history of drug abuse. 3 hearing and language expression disorders, unable to communicate; 4. Hypertensive patients, hyperthyroidism patients, diabetes patients with poor control or untreated, intolerance or allergy to ketamine, propofol, sufentanil and other drugs combined with ketamine contraindications such as glaucoma; 5. The operation type is lung wedge resection; 6, abnormal liver function (ALT and/or AST>1.5 times the upper limit of normal value or total bilirubin >=1.5 times the upper limit of normal value), abnormal renal function, serum creatinine >1.5 times the upper limit of normal value or creatinine clearance = N at screening time); Or other cardiac function abnormalities judged by the investigator to be abnormal and clinically significant; 8. Relevant researchers of this study; 9. Participated in other clinical trials within 4 weeks before surgery; 10. Can't understand the study procedure and the use of the pain scale, as judged by the researcher, and can't effectively communicate with the researcher; 11. There are other circumstances that the investigator judges are not suitable for participating in the clinical study.

Design outcomes

Primary

MeasureTime frame
MADRS depression scale score;Plasma levels of BDNF(Brain derived neurotrophic factor);visual analogue scale;

Secondary

MeasureTime frame
SF-MPQ;Postoperative opioids;The length of time;

Countries

China

Contacts

Public ContactLi Zhijian

The Second Xiangya Hospital of Central South University

53328861@qq.com+86 13787314214

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026